CRP and cancer: CRP‐lowering drugs, such as COX inhibitors and lipid‐lowering agents, have already been confirmed as effective therapeutic targets for patients undergoing cardiovascular therapy, providing promising clues for theoretical efficacy in cancer prevention and therapy 26.